Unbound MEDLINE

nilotinib journal articles from PubMed MEDLINE database

Unbound MEDLINE results for:RSS FEEDBookmark this site
nilotinib| Refine this search
1 - 10 of 264 journal articles in the PubMed databaseEmail to a friend    
 
Jabbour E, Jones D, Kantarjian HM, et al. 
Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. [JOURNAL ARTICLE]
Blood 2009 Jun 30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles 
Tomillero A, Moral MA 
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 May; 31(4):263-98.
Abstract | Full Citation
Tomillero A, Moral MA 
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 Apr; 31(3):183-227.
Abstract | Full Citation
Aguilera DG, Tsimberidou AM 
Dasatinib in chronic myeloid leukemia: a review. [Journal Article]
Ther Clin Risk Manag 2009 Apr; 5(2):281-9.
Abstract | Full Citation
Parkkila S, Innocenti A, Kallio H, et al. 
The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. [JOURNAL ARTICLE]
Bioorg Med Chem Lett 2009 Jun 6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles 
Mauro MJ 
Response Dynamics in Chronic-Phase Chronic Myeloid Leukemia. [JOURNAL ARTICLE]
Clin Lymphoma Myeloma 2009 Jun 1; 9(3):217-222.
Abstract | Full Citation | Find Related Articles 
Baldazzi C, Luatti S, Marzocchi G, et al. 
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. [LETTER]
Leuk Res 2009 Jun 12.
Full Citation | Publisher Full Text | Find Related Articles 
Breccia M, Alimena G 
Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. [Journal Article]
Curr Drug Targets 2009 Jun; 10(6):530-6.
Abstract | Full Citation
Haouala A, Zanolari B, Rochat B, et al. 
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. [JOURNAL ARTICLE]
J Chromatogr B Analyt Technol Biomed Life Sci 2009 May 13.
Abstract | Full Citation
Hadzijusufovic E, Peter B, Rebuzzi L, et al. 
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. [JOURNAL ARTICLE]
Vet Immunol Immunopathol 2009 May 18.
Abstract | Full Citation | Publisher Full Text | Find Related Articles 
New Search Next Results
  
Medical Software for Palm Pre now available

Advertise on this site.